Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats
Background/Aims: Liver X receptors (LXRα and LXRβ) are ligand-activated transcription factors that regulate expression of genes involved in lipid and cholesterol metabolism. LXR expression has been identified in the heart, and enhanced LXR activity in the streptozotocin (STZ) diabetic myocardium was...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Cell Physiol Biochem Press GmbH & Co KG
2016-06-01
|
Series: | Cellular Physiology and Biochemistry |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/445629 |
id |
doaj-e9231fca7e744f01a24dc46f8ccf84cd |
---|---|
record_format |
Article |
spelling |
doaj-e9231fca7e744f01a24dc46f8ccf84cd2020-11-24T21:30:49ZengCell Physiol Biochem Press GmbH & Co KGCellular Physiology and Biochemistry1015-89871421-97782016-06-0139135035910.1159/000445629445629Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic RatsDorota HarasiukMarcin BaranowskiPiotr ZabielskiAdrian ChabowskiJan GórskiBackground/Aims: Liver X receptors (LXRα and LXRβ) are ligand-activated transcription factors that regulate expression of genes involved in lipid and cholesterol metabolism. LXR expression has been identified in the heart, and enhanced LXR activity in the streptozotocin (STZ) diabetic myocardium was reported recently. The aim of this study was to investigate effect of in vivo LXR activation on myocardial lipid metabolism under conditions of STZ-induced diabetes. Methods: Wistar rats were randomly divided into three experimental groups: non-diabetic control, treated with STZ, and treated with STZ and LXR agonist - TO901317. Diabetes was induced by a single intraperitonal injection of STZ at a dose of 55 mg/kg. LXR agonist was administrated once daily in the morning by an oral gavage at a dose of 10 mg/kg/d during the last week of the experiment. After anesthesia samples of blood and the left ventricle were taken. Results: TO901317 administration increased expression of both LXR isoforms and its target genes: sterol response element binding protein 1c (SREBP-1c) and acetyl-coenzyme A carboxylase 1 (ACC1) in the heart of streptozotocin-diabetic rats. Treatment with LXR agonist had no effect on plasma lipids and glucose in the diabetic rats. Concomitantly, content of the examined lipid classes in the diabetic heart (nonesterified fatty acids, triacylglycerols, phospholipids, cholesterol esters, ceramide) was unchanged after treatment with TO901317. On the contrary, myocardial level of cholesterol and diacylglycerols (DAG) was decreased after LXR activation in diabetic rats, the change in DAG level was associated with downregulated expression of adipose triglyceride lipase (ATGL). Conclusion: Activation of LXRs by TO901317 protects cardiomyocytes against DAG accumulation and thus may reverse disturbances in lipid metabolism observed in streptozotocin-diabetic heart.http://www.karger.com/Article/FullText/445629MyocardiumFatty acidsDAGCardiac muscleNuclear receptorsType 1 diabetes |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dorota Harasiuk Marcin Baranowski Piotr Zabielski Adrian Chabowski Jan Górski |
spellingShingle |
Dorota Harasiuk Marcin Baranowski Piotr Zabielski Adrian Chabowski Jan Górski Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats Cellular Physiology and Biochemistry Myocardium Fatty acids DAG Cardiac muscle Nuclear receptors Type 1 diabetes |
author_facet |
Dorota Harasiuk Marcin Baranowski Piotr Zabielski Adrian Chabowski Jan Górski |
author_sort |
Dorota Harasiuk |
title |
Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats |
title_short |
Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats |
title_full |
Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats |
title_fullStr |
Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats |
title_full_unstemmed |
Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats |
title_sort |
liver x receptor agonist to901317 prevents diacylglycerols accumulation in the heart of streptozotocin-diabetic rats |
publisher |
Cell Physiol Biochem Press GmbH & Co KG |
series |
Cellular Physiology and Biochemistry |
issn |
1015-8987 1421-9778 |
publishDate |
2016-06-01 |
description |
Background/Aims: Liver X receptors (LXRα and LXRβ) are ligand-activated transcription factors that regulate expression of genes involved in lipid and cholesterol metabolism. LXR expression has been identified in the heart, and enhanced LXR activity in the streptozotocin (STZ) diabetic myocardium was reported recently. The aim of this study was to investigate effect of in vivo LXR activation on myocardial lipid metabolism under conditions of STZ-induced diabetes. Methods: Wistar rats were randomly divided into three experimental groups: non-diabetic control, treated with STZ, and treated with STZ and LXR agonist - TO901317. Diabetes was induced by a single intraperitonal injection of STZ at a dose of 55 mg/kg. LXR agonist was administrated once daily in the morning by an oral gavage at a dose of 10 mg/kg/d during the last week of the experiment. After anesthesia samples of blood and the left ventricle were taken. Results: TO901317 administration increased expression of both LXR isoforms and its target genes: sterol response element binding protein 1c (SREBP-1c) and acetyl-coenzyme A carboxylase 1 (ACC1) in the heart of streptozotocin-diabetic rats. Treatment with LXR agonist had no effect on plasma lipids and glucose in the diabetic rats. Concomitantly, content of the examined lipid classes in the diabetic heart (nonesterified fatty acids, triacylglycerols, phospholipids, cholesterol esters, ceramide) was unchanged after treatment with TO901317. On the contrary, myocardial level of cholesterol and diacylglycerols (DAG) was decreased after LXR activation in diabetic rats, the change in DAG level was associated with downregulated expression of adipose triglyceride lipase (ATGL). Conclusion: Activation of LXRs by TO901317 protects cardiomyocytes against DAG accumulation and thus may reverse disturbances in lipid metabolism observed in streptozotocin-diabetic heart. |
topic |
Myocardium Fatty acids DAG Cardiac muscle Nuclear receptors Type 1 diabetes |
url |
http://www.karger.com/Article/FullText/445629 |
work_keys_str_mv |
AT dorotaharasiuk liverxreceptoragonistto901317preventsdiacylglycerolsaccumulationintheheartofstreptozotocindiabeticrats AT marcinbaranowski liverxreceptoragonistto901317preventsdiacylglycerolsaccumulationintheheartofstreptozotocindiabeticrats AT piotrzabielski liverxreceptoragonistto901317preventsdiacylglycerolsaccumulationintheheartofstreptozotocindiabeticrats AT adrianchabowski liverxreceptoragonistto901317preventsdiacylglycerolsaccumulationintheheartofstreptozotocindiabeticrats AT jangorski liverxreceptoragonistto901317preventsdiacylglycerolsaccumulationintheheartofstreptozotocindiabeticrats |
_version_ |
1725961540730880000 |